CN111116619B - 铽掺杂的有机框架材料及其制备方法与应用 - Google Patents
铽掺杂的有机框架材料及其制备方法与应用 Download PDFInfo
- Publication number
- CN111116619B CN111116619B CN202010060035.XA CN202010060035A CN111116619B CN 111116619 B CN111116619 B CN 111116619B CN 202010060035 A CN202010060035 A CN 202010060035A CN 111116619 B CN111116619 B CN 111116619B
- Authority
- CN
- China
- Prior art keywords
- organic framework
- framework material
- terbium
- doped organic
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000463 material Substances 0.000 title claims abstract description 21
- 239000013384 organic framework Substances 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 7
- RKJXCDQOSIUDQS-UHFFFAOYSA-N 1,4-di(imidazol-1-yl)cyclohexa-2,5-diene-1,4-dicarboxylic acid Chemical group OC(=O)C1(C=CC(C=C1)(C(O)=O)n1ccnc1)n1ccnc1 RKJXCDQOSIUDQS-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000013078 crystal Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- -1 polytetrafluoroethylene Polymers 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 239000010935 stainless steel Substances 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- ZHUXMBYIONRQQX-UHFFFAOYSA-N hydroxidodioxidocarbon(.) Chemical group [O]C(O)=O ZHUXMBYIONRQQX-UHFFFAOYSA-N 0.000 claims 3
- 210000004027 cell Anatomy 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 1
- 238000004729 solvothermal method Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 8
- 238000005138 cryopreservation Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052761 rare earth metal Inorganic materials 0.000 description 3
- 150000002910 rare earth metals Chemical class 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000013241 lanthanide-based metal–organic framework Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000012621 metal-organic framework Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/008—Supramolecular polymers
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1044—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/18—Metal complexes
- C09K2211/182—Metal complexes of the rare earth metals, i.e. Sc, Y or lanthanide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种铽掺杂的有机框架材料及其制备方法与应用，该有机框架材料的化学式为C10H12N2O9Tb，其是以1,4‑双(咪唑‑1‑基)对苯二甲酸、丙二酸、Tb(NO3)3·6H2O为原料，采用溶剂热法制得。本发明制备的有机框架材料对肿瘤细胞具有明显抑制作用，且对正常细胞毒性小，故有望发展成肿瘤治疗药物。
Description
技术领域
本发明属于药物化学领域，具体涉及一种铽掺杂的有机框架材料及其制备方法与应用。
背景技术
目前稀土金属有机框架材料（Ln-MOFs）因具有独特的光电磁、催化、热稳定性质和拓扑结构，具有广阔的应用前景而备受关注，在化学、合成、材料研究领域中都取得了相当巨大的进展，但应用于药学、生物、医学领域仍较少。
1,4-双(咪唑-1-基)对苯二甲酸(
，HBTA)，是一个新合成的氮杂环化合物，其具有一定的荧光活性，兼具氮杂环化合物和芳香多羧酸的优点，N、O配位点丰富。稀土（Ln3+）金属离子具有独特的4f电子层结构，较高的正电荷导致配位数多（8~12）、配位能力强、配位模式丰富，且通常具有特殊的光电磁性。本发明以新配体HBTA与稀土金属离子设计合成出一种铽掺杂的有机框架材料。
发明内容
本发明的目的在于提供一种铽掺杂的有机框架材料及其制备方法与应用。
为实现上述目的，本发明采用如下技术方案：
一种铽掺杂的有机框架材料，其化学式为C20H24N4O18Tb2，分子量为926.62，该配合物为单斜晶系，P21/c空间群，单胞参数为a=10.2205(4) 
，b=11.0902(5) 
，c=12.5216(5) 
，α=γ=90°，β=102.769°，V=1384.19(10) 
，Z=4。
所述铽掺杂的有机框架材料的制备方法，是将1,4-双(咪唑-1-基)对苯二甲酸（HBTA）、丙二酸、NaOH溶于DMF溶液中，室温下搅拌30min后加入Tb(NO3)3·6H2O固体，混匀后置于聚四氟乙烯的不锈钢反应釜中，继续搅拌30min后于120℃恒温反应3天，再以5℃/h的速率降至室温，过滤后用蒸馏水冲洗得到无色片状晶体。
其中，所用HBTA、丙二酸、NaOH与Tb(NO3)3·6H2O的摩尔比为2:2:4:1。
所述DMF溶液中DMF与水的体积比2:8。
所得的铽掺杂的有机框架材料具有癌细胞抑制活性，可用于制备肿瘤治疗药物。
本发明的显著优点在于：
1）本发明制备的铽掺杂的有机框架材料表现出较强的癌细胞抑制活性，有望制备成肿瘤治疗药物。
2）本发明合成方法简单、经济，为配位化合物的合成提供了新的思路。
附图说明
图1为所合成配合物的配位环境。
图2为所合成配合物的三维堆积结构图（b轴方向、H原子省略）。
图3为所合成配合物的拓扑结构图。
具体实施方式
为了使本发明所述的内容更加便于理解，下面结合具体实施方式对本发明所述的技术方案做进一步的说明，但是本发明不仅限于此。
将HBTA(0.0596g，0.2 mmol)、丙二酸（0.0218g，0.2 mmol）、NaOH(0.0160g，0.4mmol)溶于10mL溶剂（去离子水:DMF=8:2，v/v）中，在室温下搅拌30min后加入Tb（NO3）3·6H2O（0.0045g，0.1mmol)固体，混匀后置于聚四氟乙烯的不锈钢反应釜中继续搅拌30min，然后在120℃恒温反应3天后，以5℃/h的速率降至室温，过滤后用蒸馏水冲洗得到C10H12N2O9Tb无色片状晶体。
1. 单晶结构分析
在体视显微镜下，挑选出合适大小、规则外形且无缺角、裂纹等明显缺陷的晶体，置于白凡士林中洗涤去粘附于表面的物质，选择并截取粗细、长短合适的玻璃丝，然后用502快速胶水将挑选单晶粘附在玻璃丝顶端之上，使晶体尽可能地直立于玻璃丝的顶端。将玻璃丝的底端固定在载晶台上，在Rigaku 18KW R-AXIS RAPID Weissenberg IP衍射仪上收集衍射强度数据，采用石墨单色器过滤的Mo-Ka射线（λ=0.71073Å），设定收集参数及扫描程序，完成后对收集的衍射强度数据进行Lp因子的校正处理。晶体的衍射强度条件和晶体数据见表1。
表1 配合物单晶的晶体学数据表
配合物（5）属于单斜晶系，P21/c空间群。Tb（Ⅲ）的配位环境如图1所示，它与一条直线上的两个HBTA上的氧原子形成两个配位键，横向三齿螯合一个丙二酸，形成一个六元环结构；另配位一个丙二酸以及三个水分子，总共8配位，Nd-O键长2.370(9) Å至2.828(9)Å。从图2三维堆积图看出，bc面由丙二酸、水分子之间的氢键将金属中心串联起来，而该二维平面通过沿a轴方向穿过的BTA层层叠加，形成三维结构的片状晶体。
2. 抗癌活性测试
PBS的制备：将药品（NaCl 8.5g， Na2HPO4•H2O 2.2g）溶于1L超纯水中，0.22μm滤膜过滤，经高压蒸汽灭菌锅灭菌，冷却后使用。
1640完全培养基的配制：向市售1640不完全培养基（500mL）中加入提前解冻的50mL胎牛血清和5mL双抗（100 U•ml-1青霉素、100 μg •ml-1链霉素），摇晃均匀，置于4℃冰箱保存。使用时，提前分装至50mL离心管。
MTT溶液的配制：称取0.025g MTT，用5mL0.01M的PBS缓冲液完全溶解，经0.22μm水性滤膜过滤，铝箔包封，现配现用。
测试方法：
1）细胞复苏与培养
液氮中里取出细胞冻存管，立即放入37℃温水浴中，轻摇使其尽快融化后，转移到离心管中，加入RPMI-1640培养基，用滴管吹打混匀后1200 r/min离心3min。弃上清，加入RPMI-1640培养基，吹打，使细胞悬浮均匀。转移到培养瓶，放入37℃、CO2培养箱静置孵育，次日用倒置显微镜观察细胞生长状况。取出培养箱里的细胞，弃培养基，加入适量PBS缓冲液漂洗细胞后弃掉。加入适量胰酶（以刚好盖住所有细胞最好），置37℃孵箱内孵育，不同细胞所需消化时间不同（通常2~5min）。倒置显微镜下观察消化细胞，若胞质回缩，细胞之间不再连接成片，表明此时细胞消化适度，立即加入适量培养基中止消化。将细胞从瓶壁上吹下，轻轻吹打混匀，离心，得到的细胞液分瓶培养，放到CO2孵箱内。一般1~2天传代一次。
2）体外细胞毒性试验(MTT)
以细胞存活率为指标，取对数生长期的三种细胞（Hela、HepG2、NCM460）进行生长抑制试验。用含10%新生牛血清的1640培养液稀释成5×104个细胞/ml，以100 μL/孔接种于96孔培养板上，在37℃、5％CO2孵箱中培养24 h使其贴壁后，分别加入用完全培养基配制的配合物溶液200μL，使样品液的终浓度分别为1.56、3.13、6.25、12.5、25、50、100μg/ml，培养48h之后PBS洗涤3次后每孔加入5 mg/ml MTT溶液10μL和完全培养基100μL，继续培养4 h后弃去液体，每孔加入150μL DMSO，避光震荡20 min，用酶标仪于490 nm测定吸光度，计算得到细胞生长存活率。以药物浓度为横坐标，细胞存活率为纵坐标，绘制药物浓度-存活率曲线，并计算半数致死量（IC50），结果见表2。
表2 配合物对不同细胞的IC50
由表2可见，该配合物对Hela细胞、HepG2细胞均表现较好的抑制效果，而对正常细胞株NCM460表现出的毒性较小，因此有望应用于肿瘤的特异性治疗。
以上所述仅为本发明的较佳实施例，凡依本发明申请专利范围所做的均等变化与修饰，皆应属本发明的涵盖范围。
Claims (5)
1. 一种铽掺杂的有机框架材料，其特征在于：其化学式为C20H24N4O18Tb2，为单斜晶系，P21/c空间群，单胞参数为a=10.2205(4)
，b=11.0902(5) 
，c=12.5216(5) 
，α=γ=90°，β=102.769°，V=1384.19(10) 
，Z=4；
所述有机框架材料中Tb（Ⅲ）与两个1,4-双(咪唑-1-基)对苯二甲酸上的羧基氧原子形成两个配位键；与一个丙二酸上的两个羧基氧原子螯合形成一个六元环结构；另与一个丙二酸上的羧基氧原子以及三个水分子中的氧原子配位，总共8配位。
2.一种如权利要求1所述的铽掺杂的有机框架材料的制备方法，其特征在于：将1,4-双(咪唑-1-基)对苯二甲酸、丙二酸、NaOH溶于DMF溶液中，室温下搅拌30min后加入Tb(NO3)3·6H2O固体，混匀后置于聚四氟乙烯的不锈钢反应釜中，继续搅拌30min后于120℃恒温反应3天，再以5℃/h的速率降至室温，过滤后用蒸馏水冲洗得到无色片状晶体。
3.根据权利要求2所述的铽掺杂的有机框架材料的制备方法，其特征在于：所用1,4-双(咪唑-1-基)对苯二甲酸、丙二酸、NaOH与Tb(NO3)3·6H2O的摩尔比为2:2:4:1。
4.根据权利要求2所述的铽掺杂的有机框架材料的制备方法，其特征在于：所述DMF溶液中DMF与水的体积比2:8。
5.一种如权利要求1所述的铽掺杂的有机框架材料在制备肿瘤治疗药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010060035.XA CN111116619B (zh) | 2020-01-19 | 2020-01-19 | 铽掺杂的有机框架材料及其制备方法与应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010060035.XA CN111116619B (zh) | 2020-01-19 | 2020-01-19 | 铽掺杂的有机框架材料及其制备方法与应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111116619A CN111116619A (zh) | 2020-05-08 |
| CN111116619B true CN111116619B (zh) | 2022-07-01 |
Family
ID=70490266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010060035.XA Active CN111116619B (zh) | 2020-01-19 | 2020-01-19 | 铽掺杂的有机框架材料及其制备方法与应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111116619B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114381010B (zh) * | 2022-02-23 | 2023-04-14 | 长治学院 | 一种三维离子型钇(ⅲ)配位聚合物、制备方法和用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110146571A (zh) * | 2019-06-05 | 2019-08-20 | 郑州轻工业学院 | 双金属有机框架复合材料及其制备方法、适体传感器及其制备方法和应用 |
-
2020
- 2020-01-19 CN CN202010060035.XA patent/CN111116619B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110146571A (zh) * | 2019-06-05 | 2019-08-20 | 郑州轻工业学院 | 双金属有机框架复合材料及其制备方法、适体传感器及其制备方法和应用 |
Non-Patent Citations (2)
| Title |
|---|
| Ratiometric fluorometric determination of the anthrax biomarker 2,6-dipicolinic acid by using europium(III)-doped carbon dots in a test stripe;Rong, Mingcong et al;《Microchimica Acta》;20181231;第185卷;第1-10页 * |
| 基于配体1,4-双（咪唑-1-基）对苯二甲酸的镧系金属配合物合成及性质研究;蒋畅;《中国优秀硕士论文全文数据库医药卫生科技辑》;20200415(第04期);第2-4章 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111116619A (zh) | 2020-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Neeraj et al. | Isolation of a Zinc Phosphate Primary Building Unit,[C6N2H18] 2+[Zn (HPO4)(H2PO4) 2] 2−, and Its Transformation to an Open-Framework Phosphate,[C6N2H18] 2+[Zn3 (H2O) 4 (HPO4) 4] 2− | |
| CN110713500B (zh) | 以2-苯甲酰吡啶缩氨基硫脲的钯配合物及其合成方法 | |
| CN111087415B (zh) | 铕掺杂的有机框架材料及其制备方法与应用 | |
| Liang et al. | Tetrachloride transition-metal dianion-induced coordination and supramolecular self-assembly of strontium dications to cucurbit [8] uril | |
| CN111116619B (zh) | 铽掺杂的有机框架材料及其制备方法与应用 | |
| CN111138680B (zh) | 具有抑菌活性的稀土金属有机框架材料及其制备方法 | |
| CN105884805B (zh) | 一种Cd(Ⅱ)混配配位聚合物及其制备方法 | |
| CN111138681B (zh) | 基于稀土金属有机框架结构的荧光材料及其制备方法 | |
| CN104788505B (zh) | 一种金属‑有机框架单晶外延生长的DMCoF/DMMnF异质结材料及其制备方法 | |
| CN108341970B (zh) | 一种基于2,5-噻吩二羧酸和钆的配位聚合物及其制备方法 | |
| Zhou et al. | Solvothermal syntheses, crystal structures and luminescence properties of three new lanthanide sulfate fluorides | |
| CN103204842A (zh) | 结晶型艾普拉唑钠水合物及其制备方法 | |
| Wang et al. | Synthesis and crystal structure of a novel potassium borate with an unprecedented [B12O16 (OH) 8] 4− anion | |
| CN113956493B (zh) | 非烷基锡氧簇合物及其合成方法及应用 | |
| CN108341969B (zh) | 一种基于2,5-噻吩二羧酸和镧的配位聚合物及其制备方法 | |
| Stephens et al. | Hydrothermal scandium fluoride chemistry: syntheses and crystal structures of [C2N2H10][ScF5],[NH4] 2 [Sc3F11] and [H3O][C6N2H16][ScF6]⋅ H2O | |
| CN103204843A (zh) | 结晶型艾普拉唑钠乙醇化物及其制备方法 | |
| Neeraj et al. | Open-framework cobalt (II) phosphates with sodalite-related architectures | |
| CN104788506B (zh) | 一种金属‑有机框架单晶外延生长的DMMnF/DMCoF异质结材料及其制备方法 | |
| CN111592498A (zh) | [2-（5′-氟尿嘧啶）乙酸-二乙基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 | |
| AU2021105917A4 (en) | Ornidazole medicine eutectic and preparation method thereof | |
| CN110818638B (zh) | 一种氮氧自由基及其制备方法和应用 | |
| CN104788507B (zh) | 一种镁掺杂金属‑有机框架DMMg0.5Mn0.5F单晶材料及其制备方法 | |
| CN109456492A (zh) | 一种含Cu(II)的金属有机骨架材料及其制备方法 | |
| Liu et al. | A novel 2D organic-inorganic hybrid 3 d–4 f polyoxometalate built by [Gd (α-PW 11 O 39) 2] 11− units and [Cu (Dap) 2] 2+ bridges |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |